---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-024605"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2022-06-29T23:59:59+00:00"
generated_at: "2026-06-24T22:22:04.216187+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports positive Phase 2b/3 PRISM trial for Haduvio in prurigo nodularis

## Summary
- Primary endpoint met: 25% of Haduvio subjects achieved 4-point WI-NRS reduction vs 14% placebo (p=0.0157).
- Significant improvement in ItchyQoL (p=0.0002) and Prurigo Activity Scale (p=0.006) at week 14.
- Safety profile consistent with prior trials; discontinuations 36.9% Haduvio vs 19.3% placebo.
- Cash and investments expected ~$78M at June 30, 2022; plans to discuss data with FDA.

## SEC filing metadata
- accession: 0001564590-22-024605
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2022-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000156459022024605/0001564590-22-024605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000156459022024605/trvi-8k_20220629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-024605
- JSON: https://secwatch.observer/filing/0001564590-22-024605.json
- Plain text: https://secwatch.observer/filing/0001564590-22-024605.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.